Sitagliptin and Its Safety for Diabetic Patients with Chronic Kidney Disease

Overview of Sitagliptin

Sitagliptin is a medication that enhances insulin secretion, showing promising safety for diabetic patients suffering from chronic kidney disease (CKD). This drug is classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, known for its efficacy in improving glycemia among CKD patients, with a favorable tolerance profile.

Mechanism of Action

The therapeutic effects of sitagliptin are linked to its ability to prolong the action of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Despite its benefits, there is limited data regarding the long-term safety and tolerability of sitagliptin.

Research Methodology

To fill this knowledge gap, researchers assessed data from 14,528 individuals aged 50 and older diagnosed with type 2 diabetes. Participants were categorized into two groups based on the presence of CKD, with 23 percent of them having the condition. The study aimed to compare various outcomes between those with CKD and those without.

Evaluation of Adverse Events

The research evaluated the incidence of cardiovascular events and other adverse outcomes, including malignancy, bone fractures, severe hypoglycemia, and diabetic complications. The findings indicated a higher incidence of these events in the CKD group compared to their counterparts without CKD.

Complications Associated with Diabetes

Additionally, the study compared the rates of diabetic-related complications—such as diabetic eye disease, neuropathy, and renal failure—among participants taking sitagliptin versus those receiving a placebo. Over a follow-up period of three years, the incidence rates of complications (neuropathy, eye disease, renal failure, and severe hypoglycemia) were similar for both groups, regardless of sitagliptin use.

Conclusion

The researchers concluded that treatment with sitagliptin did not lead to significant adverse events and was well tolerated among patients with chronic kidney disease.

Author

Written By: Vagner Raso